Table 2.

Univariate analysis of prognostic factors for overall survival and progression-free survival

Variables	OS		PFS
	HR (95% CI)	P value	HR (95% CI)	P value
Gender
Male	1		1
Female	1.109 (0.676, 1.820)	0.682	1.108 (0.686, 1.790)	0.676
Age (years)	1.009 (0.993, 1.026)	0.254	1.009 (0.994, 1.025)	0.249
Hepatitis
Hepatitis B	1		1
Other	0.690 (0.449, 1.059)	0.089	0.689 (0.454, 1.046)	0.080
Child-Pugh score
A	1
B	1.143 (0.770, 1.696)	0.509	1.001 (0.686, 1.460)	0.997
TB (µmol/L)	1.009 (0.988, 1.030)	0.417	1.014 (0.995, 1.033)	0.165
Albumin (g/L)	1.021 (0.978, 1.066)	0.345	1.002 (0.961, 1.045)	0.932
PT (s)	0.977 (0.827, 1.154)	0.785	1.102 (0.942, 1.291)	0.226
AST (µmol/L)	0.997 (0.993, 1.001)	0.173	0.997 (0.994, 1.001)	0.177
ALT (µmol/L)	0.993 (0.985, 1.001)	0.072	0.995 (0.988, 1.002)	0.192
PLR	1.002 (1.000, 1.005)	0.083	1.002 (1.000, 1.005)	0.083
NLR	1.037 (0.946, 1.136)	0.443	1.051 (0.957, 1.155)	0.301
Tumor size	1.016 (0.969, 1.065)	0.510	1.109 (0.975, 1.064)	0.404
Tumor number
≤3	1		1
≤ 3	0.991 (0.610, 1.611)	0.972	0.780 (0.482, 1.261)	0.311
α-Fetoprotein level
≥ 400 ng/mL	1		1
≤400 ng/ml	1.113 (0.768, 1.613)	0.573	0.979 (0.688, 1.394)	0.907
ECOG
1	1		1
0	0.853 (0.589, 1.234)	0.398	0.776 (0.543, 1.109)	0.164
Vascular invasion
Present	1		1
Absent	1.151 (0.795, 1.666)	0.455	1.144 (0.802, 1.632)	0.457
Extrahepatic spread
Present	1		1
Absent	1.141 (0.788, 1.653)	0.485	0.869 (0.610, 1.240)	0.439
Ascites
Present	1		1
Absent	0.778 (0.520, 1.165)	0.223	0.716 (0.485, 1.056)	0.092
Treatment method
Atez/Bev	1		1
TACE-Atez/Bev	0.651 (0.447, 0.947)	0.025	0.565 (0.392, 0.815)	0.002

OS Overall survival, PFS Progression-free survival, HR Hazard ratio, CI Confidence interval, SD Standard deviation, BCLC Barcelona Clinical Liver Cancer, TB Total bilirubin, PT Prothrombin time, AST Aspartate aminotransferase, ALT Alanine aminotransferase, PLR Platelet-to-lymphocyte ratio, NLR Neutrophil-to-lymphocyte ratio, ECOG Eastern Cooperative Oncology Group, Atez/Bev Atezolizumab/bevacizumab, TACE Transarterial chemoembolization